Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HBC.OL
- Price
- 2.35
- Stock movement down
- -0.14 (-5.62%)
- Company name
- Hofseth Biocare ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 928.43M
- Ent værdi
- 1.15B
- Pris/omsætning
- 4.18
- Pris/bog
- 6.75
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -1.18%
- 1 års afkast
- 17.50%
- 3 års afkast
- -21.72%
- 5 års afkast
- -21.28%
- 10 års afkast
- -1.95%
Senest opdateret: 2025-04-04
UDBYTTE
HBC.OL betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 4.18 |
| Pris til egenkapital | 6.75 |
| EV i forhold til salg | 5.19 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 395.08M |
| EPS (TTM) | -0.31 |
| FCF pr. aktie (TTM) | -0.09 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 221.87M |
| Bruttofortjeneste (TTM) | 63.60M |
| Driftsindkomst (TTM) | -120.44M |
| Nettoindkomst (TTM) | -121.18M |
| EPS (TTM) | -0.31 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 28.67% |
| Driftsmargin (TTM) | -54.28% |
| Fortjenstmargin (TTM) | -54.62% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 25.30M |
| Nettotilgodehavender | 27.00M |
| Omsætningsaktiver i alt | 135.82M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 45.74M |
| Ejendomme, anlæg og udstyr | 152.66M |
| Sum aktiver | 385.53M |
| Kreditor | 70.46M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 155.52M |
| Sum gæld | 247.98M |
| Aktionærernes egenkapital | 137.55M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -16.00M |
| Investeringsudgifter (TTM) | 17.84M |
| Fri pengestrøm (TTM) | -33.83M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -88.10% |
| Afkast af aktiver | -31.43% |
| Afkast af investeret kapital | -88.10% |
| Kontant afkast af investeret kapital | -24.60% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 2.49 |
| Daglig høj | 2.49 |
| Daglig lav | 2.25 |
| Daglig volumen | 72K |
| Højeste gennem alle tider | 10.91 |
| 1 års analytiker estimat | - |
| Beta | 0.34 |
| EPS (TTM) | -0.31 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 9 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| HBC.OL | S&P500 | |
| Nuværende prisfald fra top notering | -78.46% | -12.44% |
| Højeste prisfald | -89.09% | -56.47% |
| Højeste efterår dato | 3 Dec 2024 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -49.17% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 184 days | 12 days |
| Maks. tid til nyt højdepunkt | 1346 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
928.43M
Markedsværdi kategori
Small-cap
Beskrivelse
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Personale
69
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in...
10. marts 2025
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...
21. februar 2025
HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo® ...
14. februar 2025
Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis pla...
5. december 2024
HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
8. november 2024
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral...
8. oktober 2024
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72...
23. august 2024
Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically l...
14. august 2024
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate ...
2. juli 2024
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into an ...
11. juni 2024
Næste side